Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › X-linked hypophosphatemia

X-linked hypophosphatemia

Part of Malnutrition

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for X-linked hypophosphatemia

10 trials tracked for X-linked hypophosphatemia: 4 in phase 3 or 4 and 3 with published results. The most-cited published study has 366 citations.

10Trials tracked
4Phase 3 & 4
0Recruiting
3With published results
Phase distribution
Phase 4 1 Phase 3 3 Phase 2 5 Phase 1 1
  1. Phase 3 Efficacy and Safety of Burosumab Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients With XLH Completed · 366 cited
  2. Phase 3 Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH) Completed · 340 cited
  3. Phase 3 Open Label Study of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH) Completed · 17 cited
  4. Phase 4 Examining the Effect of Burosumab on Muscle Function Completed
  5. Phase 2 A Repeated Study of KRN23 in Adults With X-Linked Hypophosphatemia Completed
  6. Phase 2 Study of the Safety, Pharmacodynamics (PD) and Efficacy of KRN23 in Children From 1 to 4 Years Old With X-linked Hypophosphatemia (XLH) Completed
Show 4 more trials
  1. Phase 2 An Extension Study of KRN23 in Adults With X-Linked Hypophosphatemia Completed
  2. Phase 2 Long-Term Extension Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH) Completed
  3. Phase 2 Study of KRN23 (Burosumab), a Recombinant Fully Human Monoclonal Antibody Against Fibroblast Growth Factor 23 (FGF23), in Pediatric Subjects With X-linked Hypophosphatemia (XLH) Completed
  4. Phase 1 Calcitriol Monotherapy for X-Linked Hypophosphatemia Completed

Showing the 10 most-cited and recently-updated of 10 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
FDA Approves Crysvita (burosumab) for X-Linked Hypophosphatemia and Tumor-Induced Osteomalacia
Pediatrics FDA Approval
FDA Approves Crysvita (burosumab) for X-Linked Hypophosphatemia and Tumor-Induced Osteomalacia FDA approves new drug Crysvita for rare bone diseases in children and adults
FDA approved Crysvita (burosumab) for X-linked hypophosphatemia (XLH) in patients 6 months and older and for tumor-induced osteomalacia (TIO…
The FDA approved Crysvita (burosumab) for X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia (TIO).
FDA Apr 29, 2026
Substudy of Phase 3 trials: Nonfasting burosumab phosphorus levels in XLH patients remain stable after meals
Drug Pipeline
Substudy of Phase 3 trials: Nonfasting burosumab phosphorus levels in XLH patients remain stable after meals Burosumab Patients May Skip Fasting Before Blood Tests
This abstract describes a substudy of Phase 3 clinical trials evaluating burosumab in adults and children with X-linked hypophosphatemia.
Imagine rushing your child to a morning blood draw, stomach empty, hungry and fussy—only to find out the results might not even require fast…
Apr 24, 2026